biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Why Will Bioasis Fail?

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Jul 25, 2022 3:06pm

104 Views

Post# 34849014

RE:RE:Why Will Bioasis Fail?

Well, Aarcor, there is a certain rhetorical nature to the question and its predicate. But, alas, you're doing the same as Finallytherock is doing. You're characterizing the past and not making an argument for future failure.

Why are all the Bioasis partners ignoring past Bioasis failures? Are they differentiating between the past failures of Bioasis, the company, and xB3, the technology?

jd

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec